Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
155,379
-
Share change
-
-91,287
-
Total reported value
-
$1,539
-
Put/Call ratio
-
59%
-
Price per share
-
$2.68
-
Number of holders
-
3
-
Value change
-
-$443,003
-
Number of sells
-
8
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q2 2019
As of 30 Jun 2019,
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) was held by
3 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
155,379 shares.
The largest 4 holders included
TSP Capital Management Group, LLC, Federation des caisses Desjardins du Quebec, Advisor Group, Inc., and Kelly Financial Services LLC.
This page lists
4
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.